Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
Clinical trial NCT02493517 · COMPLETED
Trial details
- NCT number
- NCT02493517
- Sponsor
- Ipsen
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-01
- Primary completion
- 2016-11-01
- Enrollment
- 128
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.